[Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19].
K V KasyanenkoK V KozlovO V MaltsevI I LapikovV V GordienkoV V SharabkhanovP V SorokinK V ZhdanovPublished in: Terapevticheskii arkhiv (2021)
Yearly administration of riamilovir as opposed to the umifenovir and ribavirin in therapy of moderate SARS-CoV-2 infection was associated with significant shorter time to clinical improvement by 14 day of hospitalization. PCR negative rate by 7 days of hospitalization is significantly more likely in riamilovir group.